CU23820A3 - (oxazolidinon-5-il-metil)-2-tiofen-carboxamidas sustituidas y procedimiento de obtención - Google Patents

(oxazolidinon-5-il-metil)-2-tiofen-carboxamidas sustituidas y procedimiento de obtención

Info

Publication number
CU23820A3
CU23820A3 CU20090216A CU20090216A CU23820A3 CU 23820 A3 CU23820 A3 CU 23820A3 CU 20090216 A CU20090216 A CU 20090216A CU 20090216 A CU20090216 A CU 20090216A CU 23820 A3 CU23820 A3 CU 23820A3
Authority
CU
Cuba
Prior art keywords
carboxamids
oxazolidinon
metil
thiophen
replaced
Prior art date
Application number
CU20090216A
Other languages
English (en)
Other versions
CU20090216A7 (es
Inventor
Joachim Krueger
Degenfeld Georges Von
Adrian Tersteegen
Uwe Saatmann
Ulrich Rester
Stefan Heitmeier
Dirk Heimbach
Mark Jean Gnoth
Elke Dittrich-Wengenroth
Swen Allerheiligen
Susanne Roehrig
Marcus Bauser
Christoph Gerdes
Holger Paulsen
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39731148&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU23820(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of CU20090216A7 publication Critical patent/CU20090216A7/es
Publication of CU23820A3 publication Critical patent/CU23820A3/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La invención se refiere a nuevas oxazolidinonas sustituidas, a prodecimientos para su preparación, útiles para el tratamiento y/o profilaxis de enfermedades, de forma particular de enfermedades tromboembólicas. ESPACIO PARA LA FÓRMULA
CU20090216A 2007-06-20 2009-12-15 (oxazolidinon-5-il-metil)-2-tiofen-carboxamidas sustituidas y procedimiento de obtención CU23820A3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102007028319A DE102007028319A1 (de) 2007-06-20 2007-06-20 Substituierte Oxazolidinone und ihre Verwendung

Publications (2)

Publication Number Publication Date
CU20090216A7 CU20090216A7 (es) 2011-10-14
CU23820A3 true CU23820A3 (es) 2012-06-21

Family

ID=39731148

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20090216A CU23820A3 (es) 2007-06-20 2009-12-15 (oxazolidinon-5-il-metil)-2-tiofen-carboxamidas sustituidas y procedimiento de obtención

Country Status (43)

Country Link
US (2) US8383822B2 (es)
EP (1) EP2170877B1 (es)
JP (1) JP5537421B2 (es)
KR (1) KR101535312B1 (es)
CN (1) CN101821259B (es)
AR (2) AR066981A1 (es)
AU (1) AU2008266525B8 (es)
BR (1) BRPI0813736A2 (es)
CA (1) CA2692166C (es)
CL (1) CL2008001691A1 (es)
CO (1) CO6251281A2 (es)
CR (1) CR11168A (es)
CU (1) CU23820A3 (es)
CY (1) CY1113580T1 (es)
DE (1) DE102007028319A1 (es)
DK (1) DK2170877T5 (es)
DO (1) DOP2009000285A (es)
EC (1) ECSP099807A (es)
ES (1) ES2397799T3 (es)
GT (1) GT200900319A (es)
HK (1) HK1147991A1 (es)
HN (1) HN2009003424A (es)
HR (1) HRP20130072T1 (es)
IL (1) IL202351A (es)
JO (1) JO2798B1 (es)
MA (1) MA31535B1 (es)
MX (1) MX2009013711A (es)
MY (1) MY150931A (es)
NZ (1) NZ581540A (es)
PA (1) PA8784301A1 (es)
PE (1) PE20090332A1 (es)
PL (1) PL2170877T3 (es)
PT (1) PT2170877E (es)
RS (1) RS52639B (es)
RU (1) RU2481345C2 (es)
SG (1) SG182220A1 (es)
SI (1) SI2170877T1 (es)
SV (1) SV2009003435A (es)
TN (1) TN2009000503A1 (es)
TW (1) TWI413642B (es)
UA (1) UA98793C2 (es)
UY (1) UY31133A1 (es)
WO (1) WO2008155032A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006039589A1 (de) * 2006-08-24 2008-03-06 Bayer Healthcare Ag Aminoacyl-Prodrugs II
DE102007028407A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028319A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102010028362A1 (de) * 2010-04-29 2011-11-03 Bayer Schering Pharma Aktiengesellschaft Herstellverfahren
CN102464658B (zh) * 2010-11-03 2014-04-16 天津药物研究院 噁唑烷酮衍生物及其制备方法和用途
CA2824885A1 (en) 2011-01-19 2012-07-26 Bayer Intellectual Property Gmbh Binding proteins to inhibitors of coagulation factors
CN103626749A (zh) * 2012-08-21 2014-03-12 苏州泽璟生物制药有限公司 取代的噁唑烷酮化合物和包含该化合物的药物组合物及其用途
CN103232446B (zh) * 2013-05-17 2015-09-23 天津药物研究院 一种噁唑烷酮衍生物晶型ⅱ及其制备方法和用途
CN104163819A (zh) * 2013-05-17 2014-11-26 天津药物研究院 一种噁唑烷酮衍生物的乙酸溶剂化物及其制备方法和用途
CN103242307B (zh) * 2013-05-17 2015-08-12 天津药物研究院有限公司 一种噁唑烷酮类衍生物晶型ⅰ及其制备方法和用途

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
DE4319041A1 (de) 1992-10-23 1994-04-28 Bayer Ag Trisubstituierte Biphenyle
DE19642255A1 (de) 1996-10-14 1998-04-16 Bayer Ag Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten
EE9900151A (et) 1996-10-14 1999-12-15 Bayer Aktiengesellschaft Heterotsüklüülmetüül-asendatud pürasooliderivaadid
DE19649460A1 (de) 1996-11-26 1998-05-28 Bayer Ag Neue substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834045A1 (de) 1998-07-29 2000-02-03 Bayer Ag (4-Amino-5-ethylpyrimidin-2-yl)-1-(2-fluorbenzyl)-1H-pyrazolo[3,4-b]pyridin
DE19846514A1 (de) 1998-10-09 2000-04-20 Bayer Ag Neue Heterocyclyl-methyl-substituierte Pyrazole
WO2000024227A1 (en) 1998-10-16 2000-04-27 Medical Solutions, Inc. Temperature control system and method for heating and maintaining medical items at desired temperatures
DE19920352A1 (de) 1999-05-04 2000-11-09 Bayer Ag Substituiertes Pyrazolderivat
DE60022508T2 (de) 1999-06-14 2006-06-08 Eli Lilly And Co., Indianapolis Inhibitoren von serin proteasen
DE19942809A1 (de) 1999-09-08 2001-03-15 Bayer Ag Verfahren zur Herstellung substituierter Pyrimidinderivate
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
EP1242417A1 (en) * 1999-12-21 2002-09-25 PHARMACIA & UPJOHN COMPANY Oxazolidinones having a sulfoximine functionality and their use as antimicrobial agents
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
GB0114004D0 (en) 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
GB0114005D0 (en) 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
TWI257389B (en) 2001-06-12 2006-07-01 Lilly Co Eli Pharmaceutical compound
DE10129725A1 (de) 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
US7365205B2 (en) 2001-06-20 2008-04-29 Daiichi Sankyo Company, Limited Diamine derivatives
CA2452513A1 (en) 2001-07-12 2003-01-23 Pharmacia & Upjohn Company Amide-containing compound having improved solubility and method of improving the solubility of an amide-containing compound
CH1427415H1 (de) 2001-09-21 2023-12-21 Bristol Myers Squibb Holdings Ireland Lactamhaltige verbindungen und ihre derivate als faktor-xa-hemmer
TW200303201A (en) 2001-12-10 2003-09-01 Bristol Myers Squibb Co Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones
PE20040804A1 (es) 2002-12-19 2004-12-31 Boehringer Ingelheim Pharma DERIVADOS DE CARBOXAMIDAS COMO INHIBIDORES DEL FACTOR Xa
US7205318B2 (en) 2003-03-18 2007-04-17 Bristol-Myers Squibb Company Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors
DE10322469A1 (de) 2003-05-19 2004-12-16 Bayer Healthcare Ag Heterocyclische Verbindungen
US7265140B2 (en) 2003-09-23 2007-09-04 Pfizer Inc Acyloxymethylcarbamate prodrugs of oxazolidinones
CA2773066A1 (en) 2003-11-12 2005-05-26 Daiichi Sankyo Company, Limited Process for producing thiazole derivative
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
JP2005179272A (ja) 2003-12-19 2005-07-07 Yamanouchi Pharmaceut Co Ltd カルボキサミド誘導体のマロン酸塩結晶
DE102004002044A1 (de) 2004-01-15 2005-08-04 Bayer Healthcare Ag Herstellverfahren
GB0405272D0 (en) 2004-03-09 2004-04-21 Trigen Ltd Compounds
EP1893572B1 (en) 2004-06-18 2016-12-14 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
US20060069260A1 (en) * 2004-09-28 2006-03-30 Huiping Zhang Preparation of N-aryl pyridones
DE102004062475A1 (de) 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
WO2006106804A1 (ja) 2005-03-31 2006-10-12 Mochida Pharmaceutical Co., Ltd. 環内窒素原子にアシル基が結合した三環系スピロ化合物
WO2007008142A1 (en) 2005-07-08 2007-01-18 Astrazeneca Ab Heterocyclic sulfonamide derivatives as inhibitors of factor xa
AR057976A1 (es) * 2005-08-29 2008-01-09 Boehringer Ingelheim Int Biarilos sustituidos y su uso como medicamentos.
DE102005047558A1 (de) 2005-10-04 2008-02-07 Bayer Healthcare Ag Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
DE102005050375A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Tetrazol-Derivate und ihre Verwendung
DE102005050498A1 (de) 2005-10-21 2007-06-06 Bayer Healthcare Aktiengesellschaft Cyclopropylessigsäure-Derivate und ihre Verwendung
DE102005050377A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Heterocyclische Verbindungen und ihre Verwendung
DE102005050376A1 (de) 2005-10-21 2007-05-31 Bayer Healthcare Ag Dicarbonsäure-Derivate und ihre Verwendung
DE102005050497A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Difluorphenol-Derivate und ihre Verwendung
DE102006025314A1 (de) 2006-05-31 2007-12-06 Bayer Healthcare Ag Arylsubstituierte Heterozyklen und ihre Verwendung
DE102006039589A1 (de) 2006-08-24 2008-03-06 Bayer Healthcare Ag Aminoacyl-Prodrugs II
DE102007028319A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028406A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028407A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung

Also Published As

Publication number Publication date
AR066981A1 (es) 2009-09-23
HN2009003424A (es) 2012-01-05
KR20100021615A (ko) 2010-02-25
PL2170877T3 (pl) 2013-03-29
TWI413642B (zh) 2013-11-01
RU2010101307A (ru) 2011-07-27
PE20090332A1 (es) 2009-04-09
SV2009003435A (es) 2010-08-23
UY31133A1 (es) 2009-01-30
JO2798B1 (en) 2014-03-15
MA31535B1 (fr) 2010-07-01
RS52639B (en) 2013-06-28
WO2008155032A1 (de) 2008-12-24
EP2170877B1 (de) 2012-11-21
CA2692166C (en) 2015-01-27
AU2008266525B8 (en) 2013-09-19
PA8784301A1 (es) 2009-02-09
SI2170877T1 (sl) 2013-03-29
IL202351A (en) 2015-10-29
CY1113580T1 (el) 2016-06-22
CN101821259A (zh) 2010-09-01
DOP2009000285A (es) 2010-01-31
AU2008266525A1 (en) 2008-12-24
AU2008266525B2 (en) 2013-09-05
PT2170877E (pt) 2013-01-28
TW200911797A (en) 2009-03-16
IL202351A0 (en) 2010-06-30
US8846934B2 (en) 2014-09-30
RU2481345C2 (ru) 2013-05-10
CA2692166A1 (en) 2008-12-24
ES2397799T3 (es) 2013-03-11
KR101535312B1 (ko) 2015-07-09
AR067057A1 (es) 2009-09-30
DE102007028319A1 (de) 2008-12-24
BRPI0813736A2 (pt) 2014-12-30
CR11168A (es) 2010-06-28
DK2170877T5 (da) 2013-03-04
CL2008001691A1 (es) 2008-12-26
SG182220A1 (en) 2012-07-30
EP2170877A1 (de) 2010-04-07
ECSP099807A (es) 2010-01-29
UA98793C2 (ru) 2012-06-25
TN2009000503A1 (en) 2011-03-31
MX2009013711A (es) 2010-02-01
JP5537421B2 (ja) 2014-07-02
JP2010530383A (ja) 2010-09-09
CU20090216A7 (es) 2011-10-14
MY150931A (en) 2014-03-14
NZ581540A (en) 2012-01-12
CN101821259B (zh) 2013-10-30
HRP20130072T1 (hr) 2013-02-28
DK2170877T3 (da) 2013-02-11
US20140057951A1 (en) 2014-02-27
CO6251281A2 (es) 2011-02-21
US20100184740A1 (en) 2010-07-22
GT200900319A (es) 2011-11-09
US8383822B2 (en) 2013-02-26
HK1147991A1 (en) 2011-08-26

Similar Documents

Publication Publication Date Title
CU23820A3 (es) (oxazolidinon-5-il-metil)-2-tiofen-carboxamidas sustituidas y procedimiento de obtención
DOP2009000287A (es) Oxazolidinonas sustituidas y su uso
PA8784001A1 (es) Oxazolidinonas sustituidas y su uso
BRPI1013426A2 (pt) organismos para produção de 1,3-butanodiol
ECSP088358A (es) Tratamiento y profilaxis de microangiopatías
ECSP078060A (es) 2,4-diamino-pirimidinas como inhibidores de aurora
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
CR11161A (es) Procesos para la produccion de pirazoles
DOP2011000102A (es) Compuestos heteroaromaticos espirociclicos fusionados para el tratamiento de infecciones bacterianas
UY34037A (es) Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias.
BRPI1015569A2 (pt) compostos úteis para o tratamento de doenças degenerativas e inflamatórias.
CO6311079A2 (es) Derivados de aminodihidrotiazina como inhibidores de la enzima bace para el tratamiento de la enfermedad de alzheimer
ECSP11011541A (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida
ECSP11011079A (es) Nuevos compuestos de hidroxiareno.
BRPI0906618A2 (pt) Derivados de diazepinorimidona de arilamida substituídos para o tratamento de doenças neu-rodegenerativas causadas por atividade anorma de gsk3-beta
CO6382123A2 (es) Antagonistas de la via hedgehog de ftalazina disustituida
CR20150432A (es) Estra-1,3,5 (10), 16-tetraeno-3-carboxamidas para la inhibición de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3)
CU20100099A7 (es) 5-[(3,3,3-trifluoro-2-hidroxi-1-arilpropil)amino]-1h-quinolin-2-onas, un proceso para su producción y su uso como agentes antinflamatorios
HN2011000609A (es) Polimorfo b de la n-(2-aminofenil)-4-(n-(piridin-3-il) metoxicarbonilamino-metil) benzamida (ms-275)
ECSP11011483A (es) Piperidinas sustituidas
NO20084301L (no) Tetrahydronaftalenderivater, fremgangsmate for deres fremstilling og anvendelse derav som anti-inflammatoriske midler
CR11368A (es) Forma cristalina 1 de 2- ( (r)-2-metilpirrolidin-2-il) -1h-benzimidazol-4-carboxamida
CU24011B1 (es) Piperidinas 2-fenil-5-(1,2,4-oxadiazol-5-il) sustituidas
SV2009003315A (es) Nueva utilizacion para el tratamiento de las leucemias
CL2008002623A1 (es) Uso de urato oxidasa para el tratamiento o profilaxis de trastornos o secuelas indirectas del corazon provocados por sucesos isquemicos o de reperfusion.

Legal Events

Date Code Title Description
FG Grant of patent